Most recent update: Friday, October 19, 2018 - 08:09

Bariatric News - Cookies & privacy policy

You are here

Genetics

DYRK1B identified as obesity-related gene

DYRK1B promoted the expression of the key gluconeogenic enzyme glucose-6-phosphatase

A genetic mutation responsible for the cluster of cardiovascular risk factors that comprise the obesity-related metabolic syndrome, has been identified by researchers from the Yale Cardiovascular Research Center. Using whole-exome sequencing, they identified a so-called ‘founder mutation’, a genetic abnormality that begins in one ancestor and repeats through successive generations of a family.

"The entire pathway of this gene seems to be linked with glucose and fat metabolism, through the differentiation of stem cells into muscle, bone, cartilage, and fat tissue," said senior author Dr Arya Mani, associate professor of cardiology and genetics and member of the Yale Cardiovascular Research Center. "Our findings suggest that mutation in genes that regulate the fate of these cells can result in more fat instead of muscle."

For the study, which is published in the New England Journal of Medicine, the researchers studied three large families with familial, or inherited central obesity, early-onset coronary artery disease, hypertension, and diabetes.

The mutation was in the gene Dyrk1B, an enzyme that regulates the balance of muscle to fat as well as stable glucose levels by controlling the signalling pathways. When mutated, the researchers found, Dyrk1B inhibited pathways that keep glucose levels stable, and ‘turned on’ the pathways that promote the production of fat on the body.

The mutation was present in all family members affected by metabolic syndrome, and absent in those who were unaffected.

Furthermore, DYRK1B promoted the expression of the key gluconeogenic enzyme glucose-6-phosphatase. The R102C allele showed gain-of-function activities by potentiating these effects. A second mutation, substituting proline for histidine 90, was found to cosegregate with a similar clinical syndrome in an ethnically distinct family.

The researchers believe this mutated gene is the likely reason why patients with it have reduced muscle mass but increased fat mass, even at a very young age

Mani added that animal studies suggest the activation of genes like Dyrk1B may actually increase appetite and cause weight gain. Therefore, he notes, because the gene is a protein kinase, which modifies other proteins, it may be an excellent target for potential therapies that restore balance and reduce or eliminate the impact of the genetic mutation.

"The advantage of Dyrk1B as an obesity gene is that its inhibition may not only reduce body weight, but favourably affect other risk factors," added first author Dr Ali Keramati, resident in internal medicine at Yale School of Medicine.

Want more stories like this? Subscribe to Bariatric News!

Bariatric News
Keep up to date! Get the latest news in your inbox. NOTE: Bariatric News WILL NOT pass on your details to 3rd parties. However, you may receive ‘marketing emails’ sent by us on behalf of 3rd parties.